SCHEMBL19003579

SCHEMBL19003579

CCCC(CC)c1ccc(C#N)cn1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HTT P42858 1/20 0.40
ESR1 P03372 1/20 0.39
ESR2 Q92731 1/20 0.39
CYP2A6 P11509 1/20 0.35
SLC6A3 Q01959 1/20 0.34
CYP19A1 P11511 2/20 0.33
S1PR3 Q99500 3/20 0.32
KCNJ1 P48048 2/20 0.32
KCNH2 Q12809 1/20 0.32
CYP11B2 P19099 3/20 0.32
CYP11B1 P15538 1/20 0.32
PTGER4 P35408 1/20 0.31
TSHR P16473 1/20 0.31
HSD17B10 Q99714 1/20 0.31
S1PR1 P21453 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19987500 0.93 ALDH1A1 (0.41) KDM4EALDH1A1HPGDL3MBTL1HTT
SCHEMBL25573950 0.86 KDM4E (0.46) KDM4EALDH1A1HPGDL3MBTL1HTT
SCHEMBL19464638 0.84 KDM4E (0.46) KDM4EALDH1A1HPGDL3MBTL1HTT
SCHEMBL19059398 0.83 KDM4E (0.48) KDM4EALDH1A1HPGDL3MBTL1HTT
SCHEMBL21024658 0.82 KDM4E (0.40) KDM4EALDH1A1HPGDL3MBTL1HTT
SCHEMBL22363287 0.80 KDM4E (0.49) KDM4EALDH1A1HPGDL3MBTL1HTT
SCHEMBL22481391 0.78 KCNJ1 (0.43) KDM4EALDH1A1HPGDL3MBTL1HTT
SCHEMBL16311933 0.78 ALDH1A1 (0.41) KDM4EALDH1A1HPGDL3MBTL1HTT
SCHEMBL26061393 0.76 KDM4E (0.45) KDM4EALDH1A1HPGDL3MBTL1HTT
SCHEMBL19003481 0.76 ESR1 (0.42) KDM4EALDH1A1HPGDESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10398706-B2 Heteroaryldiazepine derivatives as RSV inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2019-09-03 US disclosed
US-20180193352-A1 HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS ENANTA PHARMACEUTICALS, INC. 2018-07-12 US disclosed
EP-2892899-B1 IMIDAZOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES BRISTOL MYERS SQUIBB CO (US) 2018-03-21 EP disclosed
EP-2938344-B1 PIPERAZINE-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES MERCK SHARP & DOHME (US) 2017-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10398706-B2 Heteroaryldiazepine derivatives as RSV inhibitors CYP3A5, CYP3A43, CYP3A4 KDM4E 1045/4885ALDH1A1 850/4885HPGD 717/4885
US-20180193352-A1 HETEROARYLDIAZEPINE DERIVATIVES AS RSV INHIBITORS CYP3A5, CYP3A43, CYP3A4 KDM4E 1045/4885ALDH1A1 850/4885HPGD 717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.